直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in September 2024

November 4, 2024

Authored and Edited by Daniel F. Klodowski; Umber Aggarwal; Deena Kablaoui Lanier; Nicholas A. Eitsert

In September, a relatively favorable month for patent owners, the PTAB cancelled 123 (57.75%) instituted claims across 19 IPR and PGR Final Written Decisions, including decisions issued following remand from the Federal Circuit.  After review, 74 (34.74%) instituted claims survived.  Patent owners conceded 16 (7.51%) instituted claims, including through motions to amend.  For comparison, the cumulative average cancellation rate of instituted claims in IPR, CBM, and PGR Final Written Decisions is about 74%.

On a per-case basis, no instituted or substitute claims survived in 12 (63.16%) decisions, all instituted claims survived in 6 (31.58%) decisions, and a mixed outcome occurred in 1 (5.26%) decision.  A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Final Written Decision. 

Through September 30, 2024, the PTAB has cumulatively granted 662 (15.90%) proposed substitute claims in motions to amend while denying 3,501 (84.10%) proposed substitute claims in IPRs. 

The overall cumulative instituted claim survival rate in IPRs, CBMs, and PGRs through September 30, 2024, broken down by technology center, is as follows:

The cumulative number of Final Written Decisions through September 30, 2024, separated by technology center, is as follows:

Additional cumulative statistics on the Board’s IPR, CBM, and PGR decisions, updated through September 30, 2024, are available here on the At the PTAB blog. 

Various other PTAB metrics collected and generated by Finnegan are reserved for the use of Finnegan and its clients.  Stay tuned to the At the PTAB Blog for the latest updates, analysis, and statistics on all aspects of PTAB practice.  Subscribe to receive notifications of new posts via email.

 

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Offices

Reston, VA

Washington, DC

Contacts

Daniel F. Klodowski
Partner
Washington, DC
+1 202 408 4216
Email
Umber Aggarwal
Associate
Reston, VA
+1 571 203 2423
Email
Deena Kablaoui Lanier
Associate
Washington, DC
+1 202 408 4115
Email
Nicholas A. Eitsert
Associate
Washington, DC
+1 202 408 4157
Email

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP